Human papillomavirus type 18 E7 (HPV18 E7)

Human papillomavirus type 18 E7 (HPV18 E7) is a critical oncoprotein encoded by the high-risk HPV18 virus, which is a primary causative agent of cervical and other anogenital cancers [4, 10]. The E7 protein functions as a master regulator of the host cell cycle by binding to and promoting the degradation of the retinoblastoma tumor suppressor protein (pRb) [2, 11]. This interaction leads to the constitutive release of E2F transcription factors, forcing the cell into the S-phase and promoting malignant transformation [4, 19]. Additionally, HPV18 E7 suppresses the host's innate immune system by inhibiting the cGAS-STING signaling pathway, thereby facilitating persistent viral infection [8, 9]. Therapeutic strategies targeting HPV18 E7 include DNA vaccines like VGX-3100 and GX-188E, which are designed to elicit a robust CD8+ T-cell response against infected cells [1, 12, 15]. Gene-editing technologies such as CRISPR/Cas9 are also being explored to directly target and disrupt the E7 DNA sequence within the host genome [10, 11, 14]. Because E7 expression is essential for the maintenance of the malignant phenotype in HPV-positive cancer cells, it serves as a highly specific and effective target for immunotherapy and precision oncology [2, 17].

Other names

HPV18 E7 oncoproteinE7 protein (HPV18)Human papillomavirus 18 E7HPV-18 E7

Therapeutic vaccines (DNA, viral vector, or peptide-based) induce a cytotoxic T-cell response against cells expressing the E7 oncoprotein [1, 12]. Gene-editing tools like CRISPR/Cas9, TALENs, and ZFNs directly target and disrupt the E7 gene sequence to terminate oncoprotein production [10, 11]. Experimental small molecules aim to block the E7-pRb interaction or promote E7 degradation [2, 20].